• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Hirudine variants comprising an amino acid other than the amino acid of the natural form in position 47 or 63.
    公开号:SU1687032A3
    申请号:SU874203831
    申请日:1987-11-30
    公开日:1991-10-23
    发明作者:Куртни Майкл；Дегриз Эрик；Луазон Жерар；Лемуань Ив
    申请人:Трансжен С.А. (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to medicine and can be used to create pharmaceutical compositions.
    The purpose of the invention is to increase the affinity of muteins for thrombin and simplify the method.
    Example 1. Constructions of various variants of hirudin-2 (G2) mutagenesis in vitro.
    In order to carry out directed mutagenesis in itro, the DNA fragment is cloned into the replicative form of the phage, the recombinant phage genome is isolated and hybridized with a synthetic oligonucleotide that carries the mutated sequence. This oligonucleotide serves as priming for the synthesis of a complementary strand. The double-stranded DNA thus obtained is used to transform the bacteria that will produce the phage carrying the desired mutation.
    Plasmid pTG720 represents the expression vector of hirudin in E.coll. Plasmid
    pTG730 is obtained from pTG720 by attaching the EcoR1 site of the hirudin coding sequence.
    The Cla1-EcoR1 fragment covers the entire hirudin coding region without several 5-terminal codons. This Cla l-EcoRI fragment is cloned between the sites Ass1 and EcoR1 of phage M13, termed M13T131. The phage derived from M13TG131 and containing the sequence of hirudin are termed M13TG1919.
    Three oligonucleotides are synthesized, each of which is able to pair up with the sequence 51-GTACATSGAACN-CTGAAAG-31 in M13TG1919, in addition to its central region, which corresponds to the desired mutation. The sequences of these nucleotides are as follows:
    TG435 51-CТТТЦАГГГГГГГГГГГтгтац-31,
    TG436 B TSTTTSAGGPTTSGGTGTATS-Z1,. TS43751-TsTTTSGTGTSGTsGTTGTATs-31.
    These oligonucleotides are designed to effect the substitution of the AAC codon.
    Yo
    (asn) in M13T1919 at CAC (gis) or AAA (lys), or CGC (arg), respectively.
    120 pmol of each oligonucleotide is phosphorylated in 100 µl of the reaction medium and about 20 pmol of the phosphorylated oligonucleotide is hybridized with 1 pmol of single-stranded DNA of the phage M13T1919.
    After hybridization, the mixtures are treated with Klenow polymerase and phage 14 ligase and used to transfect E. coli 71/18 strain (mutL). Cells that form ions of slow growth are selected, colonies are sown on complete medium, transferred onto 540 paper to select cells with mutated phages.
    Selection is carried out by hybridization with the primer oligonucleotide. Thus, three new phage are obtained having the desired mutated sequence: M13TG1921 (asn47-arg), M13TG1924 (asn 47 gis) and M13TG1925 (asn47 - lys).
    On the other hand, the same type of experiment was repeated with oligonucleotide T434 of sequence 5 -ATTGTAATCTCCTCTTCTG-31. This oligonucleotide is hybridized with the sequence 5 - CAGAAGAATATTTATSAAT, localized in the region Z1 of the sequence encoding G2 with an unpaired triplet intended to replace the TAT codon (tyr6 to GAG (hlu). Thus, a mutant phage corresponding to M13TG1922 (tyr63-glu) is obtained.
    Example 2. Substitution of a fragment of Pstl-HInd III and (0.6 kb) in pTG 1828 with a mutated fragment.
    Plasmid pTG1828 carries the hyrydine coding sequence, which is preceded by the genus ferromone-alpha gene sequence of the yeast MFL, all of which is under the control of the PGK promoter. The sequence of WFL and hirudin goes through a stage of synthesis and maturation in yeast, so the hirudin produced is in culture medium.
    This plasmid is used to produce mutated hirudin sequences instead of native hirudin.
    Hydrolysis with restriction enzymes Pstl and Hlndlll PTG 1828 releases five fragments of approximately 3.8; 1.9: 1.5; 1.1 and 0.6 kb respectively. The last fragment contains only one site Ass1 and one site EcoRL. The area bounded by these two sites contains the entire sequence of hirudin without several 51-terminal codons. Fragment Hindlll Pst 0,6 T. p. inserted between the Hlndlll and Pst1 vectors of the vector, which has neither the EcoR1 site, nor the Ass1 site.
    Thus, plasmid pTG1960 has one Ace 1 site and one EcoR1 site, localized at the beginning and end of the hirudin sequence.
    A large DNA fragment from the hirudin sequence is gel purified and mixed with the digestion product Ac1 - EcoR1 of the replicative form of each of the mutated phages described in Example 1,
    0 to reconstruct the pro-hirudin combination with the new G2 variants obtained by the directed mutation. Four new plasmids were selected: pTG1963 (asn47-- arg), pTG1964 (thyr63-glu), pT1965
    5 (asn47- gis) and pTS1966 (asn4D. Lys), which differ from pTG1960 only in mutated codons.
    These sequences carrying the mutated codons can be distinguished in
    0 as Pstl Hlndlll fragments and re-cloned into pTG1826 vector in place of the original Pst1-Hindlll fragment.
    Thus, four new plasmids are obtained: pTG1977 (asn4 arg), pTG1978
    5 (tyr63-Glu), pTG 1979 (asn47, gis) and pTG 1980 (asn47lys), which differ from pTG1828 described above, only by mutations.
    Example 3. Yeast TGVIsp4 cells
    0 transform with DNA pTG1977, pTG1978. pTG1979, pTG1980, Transformants are prepared in each case and four TGVIsp4 pTG1977, TGVIsp4 PTG1978, TGVIsp4 pTG1979 and TGVIsp4 strains are obtained
    5 pTG1980. The hirudin productivity of these four strains is compared to the TGVIsp4 PTG1828.
    Sow 20 ml of the culture, after 48 h of growth at 30 ° C, the cells are centrifuged (5000 rpm, 5 min) and the supernatants are analyzed.
    The TGVIsp4 culture of pTG881 (a plasmid not carrying the G2 encoding sequence) was used as a control.
    5 Supernatant activity
    evaluated for their inhibitory effect on thrombin activity (proteolytic activity on a synthetic substrate).
    It has been established that the inhibitory action is outside. produced by the variants arg4 and lys, not less than the effect of native T2. The variants Glu63 and Gis47 have a slightly lower inhibitory effect.
    Example 4. Inhibition of action
    5 thrombin.
    Variants of hirudin purified to 95% and pure human thrombin, having a percentage of activity, measured by titration of the active centers, were used, about 92%. The concentrations of thrombin are monitored in all measurements and equal to 5.5 -10 M. The reaction is carried out in a buffer of composition: 0.05 M sodium, pH 7.9, 0.18 M KCI and 0.1% PEG at 37 ° C. For 2 minutes, preincubation is carried out for thrombin and hirudin, then the reaction is started up with substrate.
    In tab. Figure 1 shows the experimentally determined amount of hirudin required to inhibit 95% of the same amount of human thrombin (5.5 M).
    Thus, it is clear that approximately four times less hirudin G2 - arg and G2 - lys is required to inhibit the same amount of human thrombin, as compared to hirudin G2.
    Therefore, the proposed variants have significantly improved inhibitory properties against thrombin.
    Example 5. Pharmacological study of two variants of hirudin - recombinant G2 and G2-Lys in comparison with standard heparin.
    The purpose of the study.
    Evaluate two variants of recombinant hirudin and compare their antithrombotic efficacy with standard heparin.
    Experimental conditions.
    The antithrombic specific activity of two recombinant hirudins in physiological serum is determined by the inhibition of the proteolytic activity of thrombin on chromoses.
    The anti-coagulant activity of the two hirudins is compared in vitro in rat and rabbit plasma for the duration of the thrombin time and the effect of the anti-EI by the chromogenic method.
    The kinetics of the plasmatic disappearance of hirudin after internal injection of a large volume is observed by measuring the effects of anti-silt using thrombin time and by the chromogenic method using calibration curves.
    The resulting plasma concentrations after 30 minutes of continuous intravenous perfusion in a rabbit were determined by the same methods.
    The antithrombic activity of two variants of hirudin and standard heparin is studied on the Wessler model in rabbits and on rats with thromboplastin as a thrombogenic agent and on the model of stasis in a rabbit. The drug is administered to the rabbit intravenously by continuous perfusion of a large volume.
    Model Wessler on the rabbit.
    Male New Zealand rabbits weighing 2.5-3 kg are used. After anesthesia, intravenous injection of sodium pentobarbital (30 mg / kg) cannilate the left carotid artery and isolate two belt veins, impose two weak ligatures on each of them at a distance of 2.5 cm from each other. Then the rabbits receive either physiological serum or solutions of hirudin or heparin by continuous perfusion for 30 minutes at a flow rate of 2.5 ml / h. 2 minutes before the end of the perfusion, arterial blood samples are taken to determine the content of plasma anticoagulants. One minute before the end of the perfusion, human standardized thromboplastin is injected at a dose of 600 ng / kg for exactly 30 seconds into the aorta through the carotid artery. After 30 seconds, the perfusion is stopped and blood stasis forms, compressing the ligature of two vein segments for 15 minutes. The belt veins are opened and thrombi are removed, washed with physiological serum and weighed after filtering onto filter paper.
    Wessler's model on the rat.
    Male Syrage-Dowley rats (DM-Obs) weighing approximately 300 g are used. After pentobarbital sodium anesthesia is administered intraperitoneally (30 mg / kg) and the median laparotomy, the inferior vena cava is released 1 cm from the renal cross. Impose two flexible ligatures at a distance of 1 cm.
    The test samples, diluted with physiological serum, were administered intravenously in a single dose of 1 ml / kg for 5 minutes 40 seconds or 1 minute (heparin) before venous stasis was realized. 40 seconds before this stasis, a thrombogenic agent was administered at a dose of 25 mg / ml / kg into the penis vein for 30 minutes. 10 seconds after the end of the injection, stasis is created, clamping both ligatures, first proximal, then distal. The state of stasis is maintained for 10 minutes, then the thrombus is removed, immersed in a 0.38% citrate solution, dried on paper to dryness and weighed the next day after drying for 1 hour at 50 ° C.
    Model of thrombosis for stagnation of blood in a rabbit.
    Male New Zealand rabbits weighing 2.5-3 kg are used. After anesthesia, by intravenous infusion of 30 mg / kg sodium pentobarbital, the left carotid artery is cannulated and two belt veins are isolated, two weak ligatures are placed on each of them 2.5 cm from each other. Then, rats or physiological serum, or solutions of hirudin or heparin were continuously perfused for 30 minutes at a flow rate of 2.5 ml / h. Two minutes before the end of the perfusion, arterial blood samples are made to determine the plasma content of the anticoagulants. After cessation of perfusion, a state of stasis is created by clamping four ligatures (first proximal, then distal). The stasis is maintained for 2 hours, then the belt veins are opened and thrombi are removed, washed in physiological serum and weighed after tamping on a paper filter.
    Results.
    For each preparation of the stock solution with a concentration of 1 mg / kg, the specific antithrombin activity of both hirudin variants with respect to human and bovine thrombin is given in Table 2.
    The specific antithrombin activity of the hirudin G2 variant is +/- 15000 ATU / mg and for the G2-Lys47 variant is +/- 19000 ATU / mg. These specific activities exceed the expected. The specific activity is identical for human and bovine thrombin.
    Anticoagulant activity in rat and rabbit plasma is equivalent at low concentrations of both hirudins. The activity of the G2-Lys47 variant is significantly higher at higher concentrations. The amount of residual thrombin in plasma, determined using a chromogenic substrate, is compared after adding both hirudins to 60 ATU / ml. For better neutralization of residual thrombin traces, the G2-Lys variant is more effective. This is expressed in the difference in the values of K.
    The kinetics of the disappearance of both hirudins in plasma after intravenous injection of a large volume is comparable in determining it by the chromogenic method, but its three definitions by thrombin time are somewhat different (Table 3).
    Hirudins disappear according to two exhibitors. In the first phase (distribution) with a half-life of 3 minutes, the initial amount in 5 minutes is reduced to 60% for both hirudins. In the second phase
    half-life is 16 minutes, for G2-Lys and 28 minutes for G2, if the calculation is carried out taking into account the thrombin time, and 28 and 30 minutes, respectively, if the chromogenic method is used. Standard heparin disappears according to one exponential phase, the half-life is 9 minutes.
    Plasma concentrations of the two variants of hirudin, obtained after 30 minutes of continuous perfusion intravenously to the rabbit, are directly dependent on the perfused doses (see Table 4). Antithrombin effects. Based on pharmacological analyzes, it can be seen that with continuous perfusion of a rabbit, the recombinant hirudin variant of G2-Lease has a higher antithrombin activity than G2 and heparin. Pharmacokinetics of both variants
    hirudin is identical.
    Studies show that the hemorrhagic hazard in rabbits or bleeding time in rats that received G2-Lease is lower than in standard heparin for each animal species at equivalent doses for a thrombosis model.
    Thus, the invention allows the production of recombinant hirudin mutants with a high pharmacological effect.
    权利要求:
    Claims (1)
    [1]
    Claim method of obtaining hirudin muteins, providing for obtaining a fragment
    DNA encoding hirudin using site-specific mutagenesis, constructing recombinant plasmid DNA encoding hirudin muteins by cloning a fragment into a vector, transforming the resulting DNA of recipient strains, cultivating the transformed strains, isolating and purifying the target product, in order increasing the affinities of muteins to thrombin and simplifying the method, a DNA fragment is obtained, in which the codon for the amino acid in position 47 of the natural HU2 form is replaced by the codon for Lys or Arg, p Combinational plasmid DNAs, pTS197ilirT61980, and Sachomicus cerevislae TGVIsp4 are used as recipients.
    1687032
    10 Table 1
    TT - thrombin time. SC - chromogenic substrate
    Table 2
    Table 3
    Table 4
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1687032A3|1991-10-23|Method for preparation of hirudin muteins
    KR0149001B1|1998-10-15|Pharmaceutical composition comprising a plaminogen activator and hirudin
    US5204323A|1993-04-20|Heparin and hirudin antidotal compositions and methods
    DK174837B1|2003-12-15|Process for producing hirudin as well as transformed yeast which can be used in the process
    CN1678636A|2005-10-05|Thrombus-resolving and anticoagulation double function fusion protein and use thereof
    JPH11504938A|1999-05-11|Kunitz-type protease inhibitor
    CA2072375C|2000-01-11|Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing saidvector and manufacturing method of products which is produced from said microorganism
    EP0651766A1|1995-05-10|BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa
    JPH07143878A|1995-06-06|Bifunctional urokinase variant having improved cellulose solubility and thrombin inhibiting action
    KR19990082479A|1999-11-25|Thrombin mutant protein, an antidote to thrombin inhibitors
    IE913601A1|1992-04-22|Megakaryocyte maturation factors
    US5876971A|1999-03-02|Thrombin inhibitor from the saliva of protostomia
    KR0147294B1|1998-08-17|Antidote for blood anticoagulants based on factor ñà
    JP2002517197A|2002-06-18|Protease inhibitor peptide
    AU682361B2|1997-10-02|Novel polypeptide having factor XA inhibitory activity
    Ohyama et al.1998|Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis
    DE4440892A1|1996-05-23|Proteins with fibrinolytic and anticoagulant properties
    JP2002241400A|2002-08-28|Blood coagulation-preventing medicinal composition for blood extracorporeal circulation route
    同族专利:
    公开号 | 公开日
    FI99211C|1997-10-27|
    JP2567263B2|1996-12-25|
    AU8188087A|1988-06-02|
    FR2607517A2|1988-06-03|
    EP0273800B1|1992-03-11|
    CS8708732A2|1991-07-16|
    EP0273800A3|1988-07-20|
    PL157254B1|1992-05-29|
    JPS63152987A|1988-06-25|
    HUT45564A|1988-07-28|
    DE3777367D1|1992-04-16|
    AT73462T|1992-03-15|
    HU213871B|1997-11-28|
    ES2032465T3|1993-02-16|
    PT86233B|1990-11-07|
    GR3004556T3|1993-04-28|
    PL269164A1|1988-08-18|
    FI875295A|1988-06-02|
    RO106890B1|1993-07-30|
    IE873239L|1988-06-01|
    AU617989B2|1991-12-12|
    NO874905D0|1987-11-25|
    KR960011918B1|1996-09-04|
    MC1884A1|1989-01-24|
    CA1341416C|2003-01-21|
    FR2607517B2|1989-12-22|
    PT86233A|1987-12-01|
    US5650301A|1997-07-22|
    CS276245B6|1992-05-13|
    DK173247B1|2000-05-22|
    FI875295A0|1987-12-01|
    EP0273800A2|1988-07-06|
    DK627687A|1988-06-02|
    NO177500B|1995-06-19|
    NO874905L|1988-06-02|
    NO177500C|1995-09-27|
    IE60544B1|1994-07-27|
    KR880007729A|1988-08-29|
    ZA879011B|1988-05-27|
    BG49719A3|1992-01-15|
    DK627687D0|1987-11-30|
    FI99211B|1997-07-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0158564B1|1984-03-27|1992-07-15|Transgene S.A.|Expression vectors for hirudin, transformed cells and process for the preparation of hirudin|
    AT64956T|1984-06-14|1991-07-15|Ciba Geigy Ag|METHOD FOR PRODUCING THROMBINE INHIBITORS.|
    DE3429430A1|1984-08-10|1986-02-20|Hoechst Ag, 6230 Frankfurt|GENE TECHNOLOGICAL METHOD FOR PRODUCING HIRUDINE AND MEANS FOR IMPLEMENTING THIS METHOD|
    DE3445517C2|1984-12-13|1993-11-18|Ciba Geigy|DNA sequence coding for a hirudin-like protein and method for producing a hirudin-like protein|
    FR2593518B1|1985-05-02|1989-09-08|Transgene Sa|VECTORS FOR THE EXPRESSION AND SECRETION OF HIRUDIN BY TRANSFORMED YEASTS|
    DE3689525D1|1985-07-17|1994-02-24|Hoechst Ag|New polypeptides with an anticoagulant effect, processes for their preparation or extraction, their use and agents containing them.|FR2628429B1|1988-03-08|1990-12-28|Transgene Sa|HIRUDINE VARIANTS, USES THEREOF AND PROCESSES FOR OBTAINING THEM|
    GB8817160D0|1988-07-19|1988-08-24|Ciba Geigy Ag|Novel proteins|
    GB8817161D0|1988-07-19|1988-08-24|Ciba Geigy Ag|Modified proteins|
    US5284768A|1988-08-24|1994-02-08|Sanofi|Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide|
    US5879926A|1989-03-31|1999-03-09|Transgene S.A.|Yeast strains for the production of mature heterologous proteins, especially hirudin|
    FR2645174B1|1989-03-31|1994-01-07|Transgene Sa|IMPROVED YEAST STRAINS FOR THE PRODUCTION OF MATURE HETEROLOGOUS PROTEINS, ESPECIALLY HIRUDIN AND PROCESS FOR PREPARING HIRUDIN|
    FR2645175B1|1989-03-31|1994-02-18|Transgene Sa|STRAIN OF SACCHAROMYCES CEREVISIA PRODUCING A HETEROLOGOUS PROTEIN AND PROCESS FOR PREPARING SAID HETEROLOGOUS PROTEIN BY FERMENTATION OF SAID STRAIN|
    FR2646437B1|1989-04-28|1991-08-30|Transgene Sa|NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME|
    FR2656531B1|1989-12-29|1992-04-24|Sanofi Sa|ARTIFICIAL PROMOTER FOR THE EXPRESSION OF PROTEINS IN YEAST.|
    US5118790A|1990-07-24|1992-06-02|Sri International|Analogs of hirudin|
    ES2093717T3|1990-11-08|1997-01-01|Japan Energy Corp|MUTANT OF HIRUDINE, ITS PRODUCTION, ANTICOAGULANT, VECTOR SECRETOR, MICROORGANISM TRANSFORMED BY THE INDICATED VECTOR AND PRODUCTION OF A PRODUCT FROM SUCH MICROORGANISM.|
    US5837808A|1991-08-20|1998-11-17|Baxter International Inc.|Analogs of hirudin|
    US5407822A|1991-10-02|1995-04-18|Sanofi|Artificial promoter for the expression of proteins in yeast|
    US20210317162A1|2019-04-16|2021-10-14|Sungen Bioscience Co., Ltd.|Method for extraction and purification of hirudin mutant and use thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR868616723A|FR2607517B2|1986-12-01|1986-12-01|VECTORS FOR EXPRESSING HIRUDIN VARIANTS IN YEAST, PROCESS AND PRODUCT OBTAINED|
    [返回顶部]